We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+31.05%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$3.42B
AUM Growth
+$931M
Cap. Flow
+$320M
Cap. Flow %
9.36%
Top 10 Hldgs %
45.63%
Holding
88
New
10
Increased
35
Reduced
24
Closed
6

Top Buys

1
FOLD
Amicus Therapeutics
FOLD
+$138M
2
BIIB icon
Biogen
BIIB
+$52.1M
3
CELG
Celgene Corp
CELG
+$46.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$37.1M
5
ALGN icon
Align Technology
ALGN
+$34.2M

Top Sells

1
ARRY
Array Biopharma Inc
ARRY
+$114M
2
CI icon
Cigna
CI
+$50M
3
MDT icon
Medtronic
MDT
+$38.2M
4
CVS icon
CVS Health
CVS
+$25.1M
5
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$20.7M

Sector Composition

1 Healthcare 94.57%
2 Financials 2.23%
3 Energy 0.01%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGRY icon
76
Surgery Partners
SGRY
$2.09B
$179K 0.01%
+15,900
New +$200K
VKTX icon
77
Viking Therapeutics
VKTX
$4.31B
$162K ﹤0.01%
16,260
– –
ADVM
78
DELISTED
Adverum Biotechnologies
ADVM
$117K ﹤0.01%
2,224
– –
ACRS icon
79
Aclaris Therapeutics
ACRS
$793M
$68K ﹤0.01%
11,320
– –
CSLT
80
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$38K ﹤0.01%
10,229
– –
CVS icon
81
CVS Health
CVS
$137B
– –
-382,400
Closed -$25.1M
IRTC icon
82
iRhythm Holdings
IRTC
$3.64B
– –
-3,910
Closed -$272K
MDT icon
83
Medtronic
MDT
$106B
– –
-419,900
Closed -$38.2M
RGEN icon
84
Repligen
RGEN
$8.31B
– –
-6,020
Closed -$317K
SBBP
85
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-12,500
Closed -$56K
NITE
86
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
– –
-1,795,846
Closed -$20.7M
1 2 3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q1 2019 Portfolio in Review

As of Q1 2019, Redmile Group held 88 positions worth $3.42B, up 37% from $2.49B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group deployed $320M of net new capital in Q1 2019, opening 10 new positions and adding to 35 existing holdings. Its largest new stake was Biogen: 165,300 shares worth $39.1M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $114M trimmed.

  • Redmile Group's largest Q1 2019 buy was Biogen: 165,300 shares worth $39.1M.
  • Redmile Group added most to Amicus Therapeutics in Q1 2019, an estimated $138M increase.
  • Redmile Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $114M.
  • Redmile Group fully exited Medtronic in Q1 2019, selling an estimated $38.2M.
  • Redmile Group's ten largest holdings make up 46% of its $3.42B portfolio in Q1 2019.
  • Redmile Group opened 10 new positions and closed 6 in Q1 2019.
  • Redmile Group's portfolio value rose 37% quarter-over-quarter to $3.42B.

Based on Redmile Group's 13F filing for Q1 2019, filed 15 May 2019.